Immunovant Inc expected to post a loss of 47 cents a share - Earnings Preview

Immunovant

31/10/2023 12:17

* Immunovant Inc  IMVT.OQ   IMVT.O  is expected to show no
change
in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Immunovant Inc is
for a
loss of 47 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Immunovant
Inc is
$48​, above​ its last closing price of $32.92. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.47       -0.45      -0.57     Missed  -27.7
 Mar. 31 2023  -0.45       -0.43      -0.46     Missed  -7.5
 Dec. 31 2022  -0.40       -0.39      -0.49     Missed  -26.1​
 Sep. 30 2022  -0.39       -0.39      -0.41     Missed  -4.8
 ​​Jun.        -0.39       -0.40      -0.35     Beat    11.6
 30 2022                                                
 Mar. 31 2022  -0.35       -0.38      -0.41     Missed  -9.1​
 Dec. 31 2021  -0.32       -0.33      -0.36     Missed  -9.9
 Sep. 30 2021  -0.26       -0.28      -0.35     Missed  -25
 This summary was machine generated October 31 at 12:17 GMT.  All
figures in US dollars  unless otherwise stated